Company news from the 07/25/06 News Brief

Share this article:
Gilead Sciences has agreed to exercise its option to purchase Corus Pharma for $365 million. Gilead anticipates that the deal will close in the third quarter of 2006. Concurrently, Gilead and Novartis Vaccine and Diagnostics have entered into an agreement whereby Novartis has agreed to dismiss its ongoing litigation with Corus for an undisclosed payment.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.